DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Large Increase in Short Interest

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 222,800 shares, an increase of 14.5% from the December 31st total of 194,600 shares. Based on an average daily trading volume, of 93,700 shares, the short-interest ratio is presently 2.4 days.

DiaMedica Therapeutics Stock Performance

NASDAQ DMAC opened at $5.76 on Monday. The firm has a market capitalization of $246.30 million, a PE ratio of -10.29 and a beta of 1.46. DiaMedica Therapeutics has a one year low of $2.14 and a one year high of $6.41. The company has a 50-day simple moving average of $5.48 and a 200-day simple moving average of $4.54.

Hedge Funds Weigh In On DiaMedica Therapeutics

Institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of DiaMedica Therapeutics in the 3rd quarter worth approximately $40,000. Blue Trust Inc. acquired a new stake in DiaMedica Therapeutics in the third quarter worth $185,000. Finally, Geode Capital Management LLC increased its position in DiaMedica Therapeutics by 29.6% in the third quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock worth $1,286,000 after buying an additional 70,070 shares during the period. 10.12% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of DiaMedica Therapeutics in a report on Friday, November 15th.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.